Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-29T06:06:48.120Z Has data issue: false hasContentIssue false
  • English
  • Français

GABA and Neuropsychiatric Disorders

Published online by Cambridge University Press:  18 September 2015

S.J. Enna
S.J. Enna*
Affiliation:
Departments of Pharmacology, Neurobiology, and Anatomy, University of Texas Medical School at Houston
*
Department of Pharmacology, University of Texas Medical School, P.O. Box 20708, Houston, Texas, U.S.A. 77025
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

During the past decade a number of reports have appeared suggesting that alterations in GABAergic transmission may play a role in the symptoms of a variety of neurosychiatric disorders (Enna, 1980; Enna and Maggi, 1979). In the present communication, some of the evidence supporting this contention will be briefly summarized and reviewed.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 7 , Issue 3 , August 1980 , pp. 257 - 259
Copyright
Copyright © Canadian Neurological Sciences Federation 1980

References

REFERENCES

Barbeau, A. (1973). GABA and Huntington’s Chorea. Lancet 2, 1499–1500.CrossRefGoogle ScholarPubMed
Bartholini, G., Scatton, B., Ziviko-Vic, B. and Lloyd, KG. (1979). On the mode of action of SL-76002, a new GABA receptor agonist. IN, GABA-Neurotrans-mitters, Krogsgaard-Larsen, P. Scheel-Kruger, J. and Kofod, H. (eds.), Munksgaard, Copenhagen, pp. 326–339.Google Scholar
Bennett, J.P., Enna, S.J., Bylund, D.B., Gillin, J.C., Wyatt, R.J. and Snyder, S.H. (1979). Neurotransmitter receptors in schizophrenic frontal cortex. Arch. Gen. Psychiat., 36, 927–934.CrossRefGoogle ScholarPubMed
Enna, S.J. (1980). Neuropharmacological and clinical aspects of ϒ-aminobutyric acid (GABA). IN, Neuropharmacology of Central and Behavioral Disorders, Palmer, G. (ed.), Academic Press, New York, in press.Google Scholar
Enna, S.J., Bennett, J.P., Bylund, D.B., Snyder, S.H., Bird, E.D. and Iversen, L.L. (1976a). Alterations of brain neurotransmitter receptor binding in Huntington’s disease. Brain Res., 116, 531–537.Google Scholar
Enna, S.J., Bird, E., Bennett, J.P., Bylund, D.B., Yamamura, H.I., Iversen, L.L. and Snyder, S.H. (1976b). Huntington’s chorea: changes in neurotransmitter receptors in brain. New Eng. J. Med., 294, 1305–1309.CrossRefGoogle Scholar
Enna, S.J., Ferkany, J.W., Van Woert, M. and Butler, I.J. (1979). Measurement of GABA in biological fluids: effects of GABA transaminase inhibitors. IN, Advances in Neurology, Vol. 23, Chase, T. Wexler, N. and Barbeau, A. (eds.), Raven Press, New York, pp. 741–750.Google Scholar
Enna, S.J. and Maggi, A. (1979). Biochemical pharmacology of GABAergic agonists. Life Sci., 24, 1727–1738.CrossRefGoogle ScholarPubMed
Enna, S.J., Stern, L.Z., Wastek, G.J. and Yamamura, H.I. (1977). Cerebrospinal fluid 7-aminobutyric acid variations in neurological disorders. Arch. Neurol., 34, 683–685.CrossRefGoogle Scholar
Ferkany, J.W. and Enna, S.J. (1980). Interaction between GABAergic agonists and the cholinergic muscarinic system in rat brain. Life Sci., in press.CrossRefGoogle Scholar
Ferkany, J.W., Strong, R. and Enna, S.J. (1980). Striatal dopamine receptor super-sensitivity in response to chronically elevated brain GABA content. J. Neuro-chem., 34, 247–249.Google Scholar
Gottesfeld, Z. (1976). Effect of lithium and other alkali metals on brain chemistry and behavior. Psychopharmacologia, 45, 239–242.CrossRefGoogle ScholarPubMed
Hornykiewicz, O., Lloyd, K.G. and Davidson, L. (1976). The GABA system and function of the basal ganglia-Parkinson disease. IN, GABA in Nervous System Function, Roberts, E. Chase, T. and Tower, D. (eds.), Raven Press, New York, pp. 479–485.Google Scholar
Iversen, L.L. Bird, E., Spokes, E., Nicholson, S.H. and Suckling, C.J. (1979). Agonist specificity of GABA binding sites in human brain and GABA in Huntington’s disease and schizophrenia. IN, GABA-Neurotransmitters, Krogsgaard-Larsen, P.Scheel-Kruger, J. and Kofod, H. (eds.), Munksgaard, Copenhagen, pp. 179–190.Google Scholar
Katz, R.I., Chase, T.N. and Kopin, I.J. (1969). Effects of ions on stimulus-induced release of amino acids from mammalian brain slices. J. Neurochem. 16, 961–967.CrossRefGoogle ScholarPubMed
Laaksonen, H., Rinne, U.K., Sonninen, V. and Riekkinen, P. (1978). Brain GABA neurons in Parkinson’s disease. Acta Neurol. Scand. Suppl. 67, 57, 282–283.Google Scholar
Lichtshtein, D., Dobkin, J., Ebstein, R.P., Biederman, J., Rimon, R. and Belmaker, R.H. (1978). Gamma-amino-butyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. Brit. J. Psychiat., 132, 145–148.CrossRefGoogle Scholar
Lloyd, K.G., and Davidson, L. (1979). H-GABA binding in brains from Huntington’s chorea patients: altered regulation by phospholipids? Science, 205, 1147–1149.CrossRefGoogle Scholar
Lloyd, K.G., Dreskler, S. and Bird, E.D. (1977b). Alterations in 3H-GABA binding in Huntington’s chorea. Life Sci., 21, 747–753.CrossRefGoogle ScholarPubMed
Lloyd, K.G., Shemen, L. and Horny-Kiewicz, O. (1977a). Distribution of high affinity sodium independent 3H-gamma-aminobutyric acid (3H-GABA) binding in the human brain: alterations in Parkinson’s disease. Brain Res., 127, 269–278.CrossRefGoogle Scholar
Maggi, A. and Enna, S.J. (1980). Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment. J. Neurochem., 34, 888–892.CrossRefGoogle ScholarPubMed
Meldrum, B.S. (1975). Gamma-aminobutyric acid and the search for new anticonvulsant drugs. Lancet, 2, 304–306.Google Scholar
Perry, T.L., Hansen, S. and Kloster, M. (1973). Huntington’s chorea, deficiency of gamma-aminobutyric acid in brain. New Eng. J. Med., 288, 337–342.CrossRefGoogle ScholarPubMed
Reisine, T.D., Fields, J.Z., Yamamura, H.I., Bird, E., Spokes, E., Schreiner, P. and Enna, S.J. (1977). Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci., 21, 335–344.CrossRefGoogle ScholarPubMed
Reisine, T.D., Yamamura, H.I., Bird, E.D., Spokes, E. and Enna, S.J. (1978). Pre-and postsynaptic neurochemical alterations in Alzheimer’s disease. Brain Res., 154, 477–481.CrossRefGoogle Scholar
Ribak, C.E., Harris, A.B., Vaughn, J.E. and Roberts, E. (1979). Inhibitory, GABA ergic nerve terminals decrease at sites of focal epilepsy. Science, 205, 211–214.CrossRefGoogle Scholar
Roberts, E. (1972). An hypothesis suggesting that there is a defect in the GABA system in schizephrenia. Neurosci. Res., Progr. Bull., 10, 468–480.Google Scholar
Snodgrass, S.R., Hedley-Whyte, E.T. and Lorenzo, A.V. (1973). GABA transport by nerve ending fractions of cat brain. J. Neurochem., 20, 771–782.CrossRefGoogle ScholarPubMed
Tamminga, C.A., Crayton, J.W. and Chase, T.C. (1978). Muscimol: GABA agonist therapy in schizophrenia. Amer. J. Psychiat. 135, 746–747.Google ScholarPubMed
Van Gelder, N.M., Sherwin, A.L. and Rasmussen, T. (1962). Amino acid content of epileptogenic human brain; focal versus surrounding regions. Brain Res., 40, 385–393.CrossRefGoogle Scholar